Nehal Lakhani - Hematology Oncology Consultants

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

559 Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)

Erika P Hamilton,Kyriakos P Papadopoulos,Minal Barve,Nehal Lakhani,Timothy F Burns,Robert A Burger, Adi Reske, Kelley Wekheye,Anthony Tolcher

Poster and E-Posters (2024)

引用0浏览0引用

Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer

Nehal Lakhani,Daphne Stewart,Debra L. Richardson, Lauren Dockery,Linda Van Le, Justin Call,Fatima Rangwala, A Schöll, Guanfang Wang,Bo Ma, Simon Metenou,Louis Gonzalez,

Journal of Clinical Oncologyno. 16_suppl (2023): 5544-5544

引用1浏览0引用

UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)

John L. Hays,Claire Frances Friedman,Nehal Lakhani,Charles K. Anderson,Joseph Buscema,Linda R. Duska,Erika P. Hamilton,Sarah E. Taylor, Cassandra Carrington,Robert Allen Burger,Theresa Louise Werner

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): TPS5613-TPS5613

引用0浏览0引用

Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC)

Debra L. Richardson,Minal A. Barve,Erika P. Hamilton,Sara Kristina Taylor,Charles K. Anderson,Joseph Buscema,Marilyn Huang,Rebecca Christian Arend,John L. Hays,Premal H. Thaker,Nehal J. Lakhani,Rebecca Mosher,

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 5545-5545

引用0浏览0引用

Phase 1 dose escalation study of SL-172154 (SIRP alpha-Fc-CD40L) in platinum-resistant ovarian cancer

Nehal J. Lakhani,Daphne B. Stewart,Debra L. Richardson, Lauren E. Dockery,Linda Van Le, Justin A. Call, Fatima A. Rangwala, Anya Scholl, Guanfang Wang,Bo Ma, Simon Metenou,Louis Gonzalez,

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (588)

Nehal Lakhani,Timothy Burns,Minal Barve,Jeffery Edenfield,John Hays,Corrine Zarwan,Theresa Werner,Charles Anderson,Joseph Buscema,Patricia Bernardo,Erika Keeton, Cassandra Carrington,

Gynecologic Oncology（2022）

引用0浏览0引用

TP024/#446 Upgrade: phase 1 combination trial of the NAPI2B-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UPRI; XMT-1536) in patients with ovarian cancer

John Hays,Theresa Werner,Nehal Lakhani, Jeffrey Edenfield,Joseph Buscema,Timothy Burns, Cassandra Carrington,Erika Keeton,Robert Burger,Charles Anderson

E-Posters (Trials In Progress) (2022)

引用1浏览0引用

Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076)

Debra Richardson,Erika Hamilton,Minal Barve,Charles Anderson,Sara Taylor,Nehal Lakhani,Joseph Buscema,Anthony Tolcher,Corrine Zarwan,Theresa Werner,John Hays,Rebecca Arend,

Gynecologic Oncology（2022）

引用3浏览0引用

Upgrade: phase 1 combination trial of the napi2b-directed antibody drug conjugate (adc) upifitamab rilsodotin (upri; xmt-1536) in patients with ovarian cancer

John Hays,Theresa Werner,Nehal Lakhani, Jeffrey Edenfield,Joseph Buscema,Timothy Burns, Cassandra Carrington,Erika Keeton,Robert Burger,Charles Anderson

Gynecologic Oncology Reports（2022）

引用0浏览0引用

PHASE 1 DOSE ESCALATION STUDY OF THE AGONIST REDIRECTED CHECKPOINT, SL-172154 (SIRP alpha-FC-CD40L) IN SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CANCER

Nehal Lakhani,Debra Richardson, Timothy Kristedja,Fatima Rangwala, Hannah McKay,Louis Gonzalez,Bo Ma,Lini Pandite,Erika Hamilton

Journal for ImmunoTherapy of Cancer (2021): A459-A459

引用6浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn